We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Electronic Nose Accurately Diagnoses Prostate Tumor Using Urine Sample

By LabMedica International staff writers
Posted on 05 Dec 2022

The diagnosis of prostate cancer using a non-invasive method and with greater accuracy than traditional diagnostic procedures is ever closer to becoming a reality. More...

This has been confirmed by the data in a study which tested the efficacy of the first prototype of an electronic nose that can identify the presence of a tumor from a urine sample, by recognizing specific volatile molecules.

Diag-Nose – the name of the project which created the first experimental prototype – is the result of close collaboration between Humanitas Mater Domini (Castellanza VA, Italy) and the Polytechnic University of Milan (Milan, Italy). The project involved 174 people divided into two groups: 88 patients with prostate cancer of varying grades and stages confirmed by a histological examination, and 86 people in the “control” group comprising men and women of different ages with no history of the disease who had undergone medical examinations (including for PSA). A urine sample was collected from each person and analyzed.

The preliminary results are encouraging. The electronic nose was found to correctly provide a positive result for patients with tumors in 85.2% of cases. It has an accuracy – that is the ability to make a correct diagnosis, whether negative or positive – of 82.1%. For men over the age of 45 only, the age range most affected by the disease but also the most difficult to correctly diagnose, the accuracy stands at 81%. The prototype has other significant benefits when compared to the traditional method of a biopsy: as well as being an invasive procedure, biopsies have a particularly high rate of false negatives for early-stage tumors due to the fact that only a small portion of tissue is collected and analyzed.

“Prostate biopsy is currently the gold standard for the diagnosis of cancer of this gland. Despite the greater precision that the procedure has achieved through the use of magnetic resonance imaging to guide the collection of the tissue samples, the tumor detection rate reaches 48.5% at the most. This percentage is significantly lower than that of the electronic nose which, in addition to greater diagnostic accuracy, would limit the inconvenience and complications for the patient”, explained the author of the study, Dr. Gianluigi Taverna, Urology Coordinator at Humanitas Mater Domini and a doctor-researcher at the Humanitas Research Hospital.

“For the electronic nose to effectively become a part of everyday clinical practice, further large-scale studies will be necessary, which will allow us to confirm the results already obtained and to develop the prototype's potential. Therefore, the next step towards making the electronic nose a reality is to validate it by involving international clinical institutes,” concluded Gianluigi Taverna and Fabio Grizzi, a researcher at the laboratories of the Humanitas Research Hospital, where he is also in charge of the histology service.

Related Links:
Polytechnic University of Milan
Humanitas Mater Domini 


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.